Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2022 Earnings Conference Call February 14, 2023 4:30 PM ET

Corporate Participants

Karina Calzadilla - VP, Investor Relations

Tycho Peterson - Chief Financial Officer

Sharon Benzeno - Chief Commercial Officer, Immune Medicine

Nitin Sood - Chief Commercial Officer, MRD

Chad Robins - Co-founder, Chairman and Chief Executive Officer

Conference Call Participants

Derik De Bruin - Bank of America

David Westenberg - Piper Sandler

Daniel Brennan - Cowen

Julia Cheng- JPMorgan

Mark Massaro - BTIG

Elizabeth Webster - Goldman Sachs

Andrew Brackmann - William Blair

Sung Ji Nam - Scotia Bank

Dan Leonard - Credit Suisse

Operator

Good day and thank you for standing by and welcome to the Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Karina Calzadilla. You may go ahead.

Karina Calzadilla

Thank you, Justin, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies fourth quarter and full year 2022 earnings conference call. Earlier today, we issued a press release reporting Adaptive financial results for the fourth quarter and full year of '22. The press release is available at www.adaptivebiotech.com.

We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the Investors section in our corporate website. During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company.

These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and listed in this presentation.

In addition, non-GAAP financial measures will be discussed during this call, and a reconciliation of non-GAAP to GAAP metrics can be found in our earnings release. Joining the call today are Chad Robins, our CEO of Co-founder; and Tycho Peterson, our Chief Financial Officer.

In addition, Harlan Robins, Adaptive Chief Scientific Officer and Co-founder; Nitin Sood, Head of MRD business; and Sharon Benzeno, Head of Immune Medicine business will be available for Q&A.

With that, I'll turn the call over to Chad Robins. Chad?

Chad Robins

Thanks, Karina.

Good afternoon, everybody. And thank you for joining us on our 2022 fourth quarter and full year earnings call. As always, I want to thank all of our Adaptive employees for their dedication and strong execution throughout the year.